MUTATION SPECTRUM OF DUCHENNE MUSCULAR DYSTROPHY PATIENTS IN INDIAN POPULATION

@article{Mathur2020MUTATIONSO,
  title={MUTATION SPECTRUM OF DUCHENNE MUSCULAR DYSTROPHY PATIENTS IN INDIAN POPULATION},
  author={Priyanshu Mathur and Ansh Agarwal and Kashish Goyal and Avisha Mathur},
  journal={Israel Journal of Chemistry},
  year={2020},
  volume={07},
  pages={247-250}
}
Background: Duchenne muscular dystrophy (DMD) is the most common X-linked neuromuscular disorder in children. Since the novel, DMD therapies are mutation-specific, so detection of mutation is of paramount importance in planning the treatment of DMD patients. Objective: The objective of this study was to find different mutations present in DMD patients in Indian population. Materials and Methods: This study was a hospital-based retrospective observational study conducted from December 2018 to… 

References

SHOWING 1-10 OF 16 REFERENCES
Genetic and clinical profile of patients of Duchenne muscular dystrophy: Experience from a tertiary care center in Eastern India
TLDR
The positivity of PCR- based diagnosis is higher in this study possibly related to highly selective group of patients, and Phenotype and genotype correlation was not seen.
Study of Dystrophinopathy in Eastern Uttar Pradesh Population of India
TLDR
It is concluded that mid-distal region of dystrophin is highly polymorphic in the population of eastern Uttar Pradesh and responsible for pathogenesis of DMD.
Duchenne Muscular Dystrophy: From Diagnosis to Therapy
TLDR
Duchenne muscular dystrophy is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene, which has opened novel avenues in molecular biology, medical genetics and novel therapeutic options.
Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.
TLDR
The combination of cDNA hybridizations with long-range analysis of deletion and duplication patients yields a global picture of the exon spacing within the dystrophin gene.
Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)
  • R. Finkel
  • Biology
    Journal of child neurology
  • 2010
TLDR
Use of nonsense mutation suppression in Duchenne/Becker muscular dystrophy may offer the prospect of targeting the specific mutation causing the disease and correcting the fundamental pathophysiology.
Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.
TLDR
A novel approach to correct dystrophin deficiency at the post-transcriptional level by transfection of muscle cells with antisense RNA, which may in the future offer a therapeutic approach for DMD, as well as for other inherited disorders.
PTC124 targets genetic disorders caused by nonsense mutations
TLDR
The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
Chronicles in drug discovery.
TLDR
This month's Chronicle in Drug Discovery highlights agents that target and deplete immunosuppressive regulatory T cells, which are produced by tumor cells to hinder innate immunity against, or chemotherapies targeting, tumor-associated antigens.
CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective.
TLDR
An overview of the current application and the prospect of CRISPR/Cas9 technology, particularly in stem cell research and therapy is provided.
...
1
2
...